Ashley Carr
Psychiatric/Mental Health · Fargo, NDNPI 1588140024
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Alkermes, Inc. at 30.3% of the total. Reporting peaked in 2021 at $260 and has fallen 88.2% since, to $31 in 2025.
Across 30 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$147
- Neurocrine Biosciences, Inc.$144
- Otsuka America Pharmaceutical, Inc.$50
- Johnson & Johnson$45
- AbbVie$34
- Teva Pharmaceuticals USA, Inc.$27
- plus $37 from 2 others
What the payments were for
- Food & beverage$483100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 9 | $147 |
| Neurocrine Biosciences, Inc. | 9 | $144 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Johnson & Johnson | 3 | $45 |
| AbbVie | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| TG Therapeutics, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $13 |
How this compares
$483 in reported general payments places this provider in the 65th percentile of 92 psychiatric/mental health providers in North Dakota.
See all psychiatric/mental health providers in North Dakota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 11 | $3,939 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 19 | $697 |
| Olanzapine | 51 | $670 |
| Ziprasidone Hcl | 24 | $555 |
| Bupropion Hcl | 11 | $509 |
| Risperidone | 27 | $499 |
| Escitalopram Oxalate | 57 | $499 |
| Quetiapine Fumarate | 41 | $353 |
| Bupropion XlBupropion Hcl | 22 | $314 |
| Aripiprazole | 17 | $173 |
| Lamotrigine | 41 | $132 |
| Hydroxyzine Hcl | 11 | $120 |
| Mirtazapine | 24 | $117 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 12 | $95 |
| Trazodone Hcl | 28 | $81 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Fargo
- Jessica Graham SteinhauerFargo$8K
- Linda VolnessFargo$2K
- Viola NwachukwuFargo$1K
- Joanna JohnsonFargo$999
- Leah Victoria HornerFargo$856
- Maryn YoungFargo$822
- Jordyn BuckmierFargo$748
- Erin DiciollaFargo$654
- Sarah TerpstraFargo$445
- Erika YoneyFargo$357
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.